Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

Fig. 1

Progression-free survival of first-line EGFR-TKIs in lung adenocarcinoma patients harboring EGFR sensitizing mutations. a overall cohort; b in patients with Exon 19 deletion; c in patients with L858R mutation; d in patients with cavitary adenocarcinoma according to mutational status; e in patients with cavitary adenocarcinoma according to the thickness of cavity wall. Abbreviations: EGFR-TKI, epidermal growth factor receptor- tyrosine kinase inhibitor

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us